Introduction
============

Polypoidal choroidal vasculopathy (PCV) usually presents with hemorrhagic or exudative maculopathy. It is characterized by polypoidal lesions with or without branching vascular network (BVN). The prevalence of PCV in Asian patients is higher than in other populations and by up to 50% in some series.[@b1-opth-12-2177] Many studies demonstrated the treatment options of PCV, such as photodynamic therapy (PDT), intravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) or steroids, and the combination treatment with various treatment outcomes. The EVEREST study[@b2-opth-12-2177] was the first to show the benefit of the combination of PDT and anti-VEGF injection in terms of complete polyp regression. However, other studies[@b3-opth-12-2177],[@b4-opth-12-2177] reviewed different outcomes from PDT and the combination regimen. Recently, EVEREST II study[@b5-opth-12-2177] has described the results of a combination of initial PDT and ranibizumab, and it showed better visual results than monotherapy of ranibizumab injections. In contrast, the Planet study[@b6-opth-12-2177] demonstrated favorable outcomes from a monotherapy injection of aflibercept. Nevertheless, we still do not know the treatment outcomes from real-life experiences that could not use the same treatment regimens as described by the standard studies.

Methods
=======

This is a real-life retrospective review of 651 patients with presumed age-related macular degeneration (AMD), who presented at Songklanagarind Hospital, Southern Thailand, from 2011 to 2014. The study was approved by the Human Research Ethics Committee, Faculty of Medicine, Prince of Songkla University, on 20 July 2017. We reviewed the patient files, fundus photographs, fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT) by three retinal specialists. Diagnosis of PCV followed the diagnostic criteria of the EVEREST study,[@b2-opth-12-2177] and the diagnostic agreement of at least two of the three specialists was required. The inclusion criteria were patients with clinical AMD, such as exudative, hemorrhagic, or serosanguineous maculopathy. The exclusion criteria were patients previously treated with PDT or intravitreal injections of anti-VEGF or steroids or patients with central serous chorioretinopathy, diabetic retinopathy, secondary choroidal neovascularization, and other macular conditions that were not compatible with AMD. All patients had to complete at least a 1-year follow-up. The authors collected as much data as possible, such as best-corrected visual acuity (BCVA; logMAR, using ETDRS charts), central retinal thickness (CRT) using spectral domain OCT (Spectralis; Heidelberg Engineering Inc., Heidelberg, Germany), treatments (PDT, anti-VEGF injections, and others), time between treatments, follow-up times, number of injections, and other treatments.

Results
=======

A total of 651 patients with presumed AMD were reviewed, and 201 patients (242 eyes) were diagnosed with PCV. This showed a prevalence of 30.8%. After excluding the patients with less than a 1-year follow-up, 171 patients (201 eyes) were included in the study analysis. At the beginning, 195 eyes received monotherapy of anti-VEGF injections, either bevacizumab or ranibizumab, and only six eyes received the combination of anti-VEGF injection and PDT at the time of the first treatment. The anti-VEGF injections were scheduled only when the disease showed an active condition ("prn" or "as need" injection). During follow-up, many patients received "rescue or add-on" PDT when they had a poor response or recurrence after multiple anti-VEGF injections. The poor response or recurrence was clarified or decided by the clinician preferences (mainly because of BCVA drop or new subretinal fluid from OCT).

Although this review was a retrospective study, all baseline demographic data were similar in both combination and anti-VEGF monotherapy groups, including BCVA, CRT, age, gender, and eye side ([Table 1](#t1-opth-12-2177){ref-type="table"}). The average follow-up time was 3.35 years, and 67% of eyes completed a 4-year follow-up. At the beginning, 195 eyes received monotherapy injection of anti-VEGF, and only six eyes received the combination of anti-VEGF injection and "initial" PDT at the time of the first treatment. At the end of the fourth year, 79 eyes received only monotherapy injection of anti-VEGF and 55 eyes received at least one of the combination regimens during their follow-up ([Table 2](#t2-opth-12-2177){ref-type="table"}).

After a 4-year follow-up, the average number of injections was 8.25 and 9.15 for the anti-VEGF monotherapy and the combination groups, respectively. The number of injections was similar in both groups from the first to the fourth year ([Table 3](#t3-opth-12-2177){ref-type="table"}). In the combination group, the average number of PDT was 1.26 times within the 4-year follow-up period. Interestingly, the average time between the first anti-VEGF injection and the first PDT was 21.4 months. This finding indicates that most of the patients received rescue or add-on PDT in the second year of the treatment, or it meant that PDT was performed a long time after the first anti-VEGF injection.

The BCVA and CRT changes from OCT were also similar in both groups. At the end of the fourth year, the BCVA in the anti-VEGF monotherapy group had increased by an average of 1.5 letters (−0.03 logMAR), whereas it had decreased by an average of 0.95 letters (+0.019 logMAR) in the combination group (*P*=0.48; [Figure 1](#f1-opth-12-2177){ref-type="fig"}). Nevertheless, the OCT or CRT changes showed interesting results, demonstrating the benefit of the combination treatment, especially in the third year ([Figure 2](#f2-opth-12-2177){ref-type="fig"}). For the categories of visual acuity (VA) changes, gain or loss, the data showed that the proportion of patients with VA gain or loss were also similar in both groups for most of the categories of VA changes ([Table 4](#t4-opth-12-2177){ref-type="table"}).

Discussion
==========

The review demonstrated a prevalence of PCV in Thai patients of 30.8%, which is comparable with other Asian populations. This finding means that about one-third of Thai patients with presumed AMD would have PCV. Our prevalence was lower than the previous Thai PCV study[@b1-opth-12-2177] because we used the EVEREST-diagnostic criteria strictly, and all diagnoses were made by at least two of three experts in agreement. However, this was not a real "prevalence" because the review was retrospective and not an exact population-based study. In our real-life practice, most patients received anti-VEGF injection as the first line of treatment, followed by rescue or add-on PDT only when they had a poor response or recurrence from multiple injections. Our rescue or add-on was different from "rescue" PDT of the Planet study[@b6-opth-12-2177] in terms of lacking strict treatment protocols and depending on only clinicians' preferences or decisions. Therefore, our results could not be directly compared with the results from the Planet study. Moreover, our combination regimen was also different from that of the EVEREST II study that used PDT as the initial treatment with anti-VEGF injection.

From the review, our real-life treatment regimens could be divided into two main groups: the first was the monotherapy prn anti-VEGF injection and the second was a combination of prn anti-VEGF injection and rescue or add-on PDT. The VA results were similar in both groups from the first to fourth year. All categories of VA changes, either VA gain or loss, were also similar. The average VA changes compared to baseline were increases of 1.5 letters and decreases of 0.95 letters in the monotherapy anti-VEGF injections and the combination groups, respectively. In general, VA was lower than the results from standard studies[@b2-opth-12-2177]--[@b6-opth-12-2177] because our review was conducted in real-life practice and we did not use the injection protocol strictly, leading to lower visual outcomes. Moreover, when compared with the EVEREST II study, our results did not demonstrate the BCVA benefit from the combination regimen. These findings might come from two possible reasons. First, our PDT was done in nonresponsive cases that usually had poorer vision; thus, the additional effect of PDT might not overcome the better visual results from the monotherapy group. Second, the rescue or add-on PDT itself might have been less effective than the initial combination regimen in terms of visual outcomes. Our review used PDT at the average time of 21.4 months, which was a long time after the first injection. Hence, this might give different results from the combination study of initial or "early" PDT as shown by the EVEREST II and Fujisan studies.[@b4-opth-12-2177],[@b5-opth-12-2177] We postulated that the multiple anti-VEGF injections might change some histological structures of the polyps or BVN and some treatment responses from PDT. This hypothesis also explains the finding from the EVEREST II study that showed the benefit of PDT because it used PDT only as the initial treatment with anti-VEGF injection. Therefore, from all the recent data, if we consider the combination regimen for PCV treatment, we might better choose initial rather than rescue or add-on PDT.

The CRT studies from the review also showed similar results in both treatment groups, except in the third year that demonstrated some benefit of the combination regimen. These findings might be the effect of PDT in the second to third year because most of our patients received rescue or add-on PDT at the average time of 21.4 months. The treatment in the second year would make the CRT thinner in the third year, although it did not affect the visual outcomes as described.

The limitation of this study was its retrospective design. The design could not control many treatment protocols or schedules. The reinjection criteria were planned only by the experts' opinions and made our regimens and results different from the standard studies. However, the results could give us the answers about real-life practices and the treatment results of PCV, especially in Thailand. The recurrent rates were also difficult to determine because there were many reinjections for different reasons during this long-term follow-up review. Moreover, because some of the cases in our review received both bevacizumab and ranibizumab, we could not evaluate the different effects of both drugs on the visual outcomes. This limitation might be a major confounding factor of this retrospective review.

Conclusion
==========

Our real-life review demonstrated the same visual treatment outcomes between the combination therapy of anti-VEGF injections and "add-on" PDT vs monotherapy prn anti-VEGF injections in PCV treatment. When compared with the EVEREST II and the Planet studies, the "initial" or "rescue or add-on PDT" might have different effects on the final visual outcomes.
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![The BCVA changes from the baseline for the combination and anti-VEGF groups at each year.\
**Abbreviations:** BCVA, best-corrected visual acuity; anti-VEGF, anti-vascular endothelial growth factor.](opth-12-2177Fig1){#f1-opth-12-2177}

![The CRT changes from the baseline for the combination and anti-VEGF groups at each year.\
**Note:** \**P*-value with statistical significance.\
**Abbreviations:** CRT, central retinal thickness; anti-VEGF, anti-vascular endothelial growth factor.](opth-12-2177Fig2){#f2-opth-12-2177}

###### 

The demographic data

  Characteristics                    n (%) or mean±SD (171 patients, 201 eyes)
  ---------------------------------- -------------------------------------------
  Gender                             
   Male                              87 (50.9)
   Female                            84 (49.1)
  Mean age at PCV diagnosis, years   68.46±9.24
  Laterality                         
   Right eye                         80 (46.8)
   Left eye                          61 (35.7)
   Both eyes                         30 (17.5)
  At baseline                        
   BCVA (logMAR)                     0.61±0.51
   CRT (µm)                          290.39±112.15

**Abbreviations:** PCV, polypoidal choroidal vasculopathy; BCVA, best-corrected visual acuity; CRT, central retinal thickness; logMAR = Logarithm of the minimum angle of resolution.

###### 

The cumulative number of patients for each group at each year

  Year                 n (%)
  -------------------- ------------
  First year           
   Combination group   34 (16.9)
   Anti-VEGF group     167 (83.1)
  Second year          
   Combination group   47 (23.7)
   Anti-VEGF group     151 (76.3)
  Third year           
   Combination group   57 (33.3)
   Anti-VEGF group     114 (66.7)
  Fourth year          
   Combination group   55 (41.0)
   Anti-VEGF group     79 (59.0)

**Abbreviation:** anti-VEGF, anti-vascular endothelial growth factor.

###### 

The number of injections at each year

  Year          Combination   Anti-VEGF   *P*-value
  ------------- ------------- ----------- -----------
                                          
  First year    3.65±2.31     3.04±2.00   0.116
  Second year   1.85±1.99     1.22±1.82   0.056
  Third year    1.83±2.04     1.97±2.23   0.672
  Fourth year   2.16±2.22     2.04±2.16   0.743

**Abbreviation:** anti-VEGF, anti-vascular endothelial growth factor.

###### 

The number of patients for categories of VA changes at each year

  BCVA                   Combination (n, %)   Anti-VEGF (n, %)   *P*-value
  ---------------------- -------------------- ------------------ -----------
                                                                 
  First year                                                     
   BCVA gain \>1 line    7 (20.6)             60 (35.9)          0.110
   BCVA gain \>2 lines   6 (17.6)             47 (28.1)          0.286
   BCVA gain \>3 lines   5 (14.7)             29 (17.4)          0.807
   BCVA loss ≤1 line     25 (73.5)            143 (85.6)         0.124
   BCVA loss ≤2 lines    26 (76.5)            151 (90.4)         0.038^\*^
   BCVA loss ≤3 lines    27 (79.4)            152 (91.0)         0.067
  Second year                                                    
   BCVA gain \>1 line    13 (27.7)            59 (39.1)          0.169
   BCVA gain \>2 lines   10 (21.3)            40 (26.5)          0.566
   BCVA gain \>3 lines   6 (12.8)             11 (13.9)          1.000
   BCVA loss ≤1 line     34 (72.3)            122 (80.8)         0.225
   BCVA loss ≤2 lines    38 (80.9)            133 (88.1)         0.227
   BCVA loss ≤3 lines    38 (80.9)            137 (90.7)         0.073
  Third year                                                     
   BCVA gain \>1 line    21 (36.8)            43 (37.7)          1.000
   BCVA gain \>2 lines   13 (22.8)            30 (26.3)          0.710
   BCVA gain \>3 lines   7 (12.3)             17 (14.9)          0.816
   BCVA loss ≤1 line     46 (80.7)            85 (74.6)          0.445
   BCVA loss ≤2 lines    48 (84.2)            95 (83.3)          1.000
   BCVA loss ≤3 lines    49 (86.0)            100 (87.7)         0.810
  Fourth year                                                    
   BCVA gain \>1 line    18 (32.7)            25 (31.6)          1.000
   BCVA gain \>2 lines   10 (18.2)            20 (25.3)          0.402
   BCVA gain \>3 lines   5 (9.1)              11 (13.9)          0.433
   BCVA loss ≤1 line     43 (78.2)            53 (67.1)          0.178
   BCVA loss ≤2 lines    47 (85.5)            62 (78.5)          0.371
   BCVA loss ≤3 lines    48 (87.3)            68 (86.1)          1.000

**Abbreviations:** VA, visual activity; BCVA, best-corrected visual acuity; anti-VEGF, anti-vascular endothelial growth factor.
